Ask VialBase
metabolic

AOD-9604

Also known as: Anti-Obesity Drug 9604, hGH Fragment 176-191, Tyr-hGH177-191, AOD9604
FDA: Not FDA-approved WADA: Prohibited at all times

AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to the C-terminal portion of human growth hormone (amino acids 176-191), with an additional N-terminal tyrosine residue. Developed by Metabolic Pharmaceuticals in Australia, it was designed to retain the fat-metabolizing properties of growth hormone while eliminating its growth-promoting, diabetogenic, and IGF-1-stimulating effects. AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through a mechanism involving the beta-3 adrenergic receptor pathway. In 2013, the FDA granted it Generally Recognized As Safe (GRAS) status for use as a food ingredient. While clinical trials for obesity were discontinued, AOD-9604 has found renewed

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 1,815.08 Da
Half-life ~30-45 minutes
CAS number —
Route Subcutaneous · Oral (under investigation) · Intra-articular (cartilage) subcutaneous preferred
02

Mechanism

Modified C-terminal fragment of human growth hormone (hGH 176-191) — stimulates lipolysis and inhibits lipogenesis without affecting IGF-1, blood glucose, or growth; beta-3 adrenergic receptor pathway modulation

03

Dosing

DOSE RANGE 250–500 mcg
FREQUENCY 1x daily
CYCLE LENGTH 12-20 weeks

Inject on empty stomach (fasting), typically morning before food. Clinical trials used 1mg/day oral. SubQ protocols typically 250-500 mcg daily. Often combined with diet/exercise protocols.

04

Research summary

Study Type Year Key Finding
AOD-9604 stimulates proteoglycan synthesis in chondrocytes Preclinical (in vitro/in vivo) 2015 AOD-9604 stimulated proteoglycan synthesis in chondrocytes
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Narrative review 2026 AOD-9604 among unapproved peptides marketed directly to patients
AOD-9604 Phase IIb Obesity Trial and Development History Development history summary 2004-2007 Phase IIb RCT with 300+ patients for oral AOD-9604 (1mg/day)
05

Stacking & interactions

Fat loss + GH support without full GH side effects

Fat loss + GH secretagogue stack

Fat metabolism + tissue repair

Metabolic optimization + cellular energy

Stacks containing AOD-9604

Fasted Burner

Tesamorelin + Amlexanox + AOD-9604

GH-Boost Metabolic

CJC-1295 (w/ DAC) + Ipamorelin + AOD-9604

Shred

AOD-9604 + MOTS-c + 5-Amino-1MQ

28-day resets featuring AOD-9604

06

Sourcing

Current prices

Updated today

5mg

10mg

Only vendor stocking this size on the VialBase roster.

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 20% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep
Stocks this compound Third-party tested Public COAs

Save 50% via this link — discount auto-applied at checkout.

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • Fasting Glucose
  • Fasting Insulin
  • CMP
  • CBC
  • Lipid Panel
DURING CYCLE
  • Fasting Glucose
  • Fasting Insulin
POST-CYCLE
  • Fasting Glucose
  • Lipid Panel
Safety & Regulatory Status
FDA STATUS Not FDA-approved. GRAS (Generally Recognized As Safe) status granted by FDA for use as a food ingredient (2013). FDA 503A Category 2 bulk drug substance
WADA STATUS Prohibited at all times (S2 — Peptide Hormones, Growth Factors)

Regulatory status for AOD-9604 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

References

  1. Various. AOD-9604 stimulates proteoglycan synthesis in chondrocytes. Various (2015). PMID: 26578461
  2. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med (2026). PMID: 41966639
  3. Metabolic Pharmaceuticals (now Calzada Ltd). AOD-9604 Phase IIb Obesity Trial and Development History. Company/regulatory filings (2004-2007).